Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) insider Mayukh Sukhatme sold 172,899 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $37.17, for a total transaction of $6,426,655.83. Following the sale, the insider directly owned 18,630,739 shares in the company, valued at approximately $692,504,568.63. The trade was a 0.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Mayukh Sukhatme also recently made the following trade(s):
- On Friday, August 21st, Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock. The stock was sold at an average price of $36.48, for a total transaction of $5,280,698.88.
- On Thursday, August 20th, Mayukh Sukhatme sold 17,519 shares of Roivant Sciences stock. The shares were sold at an average price of $37.30, for a total transaction of $653,458.70.
- On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The shares were sold at an average price of $36.23, for a total transaction of $8,810,302.71.
- On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The shares were sold at an average price of $36.25, for a total transaction of $10,320,628.75.
- On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The stock was sold at an average price of $36.73, for a total transaction of $5,029,879.66.
Roivant Sciences Stock Down 1.5%
ROIV traded down $0.54 on Friday, reaching $36.30. The company had a trading volume of 6,185,493 shares, compared to its average volume of 5,631,176. Roivant Sciences Ltd. has a 1 year low of $11.60 and a 1 year high of $37.97. The stock has a market capitalization of $26.22 billion, a PE ratio of -68.49 and a beta of 1.12. The stock has a 50-day moving average price of $34.61 and a 200-day moving average price of $30.43.
Hedge Funds Weigh In On Roivant Sciences
Several institutional investors have recently added to or reduced their stakes in ROIV. SBI Securities Co. Ltd. grew its stake in shares of Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after purchasing an additional 1,166 shares during the last quarter. Allworth Financial LP raised its stake in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares during the last quarter. Kestra Advisory Services LLC acquired a new stake in shares of Roivant Sciences during the fourth quarter worth $47,000. Parallel Advisors LLC lifted its holdings in shares of Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after purchasing an additional 520 shares during the period. Finally, CIBC Private Wealth Group LLC lifted its holdings in shares of Roivant Sciences by 7,614.3% during the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after purchasing an additional 2,665 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.
Analyst Ratings Changes
Several research firms have commented on ROIV. HC Wainwright lifted their price target on Roivant Sciences from $34.00 to $41.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Sanford C. Bernstein upgraded shares of Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Roivant Sciences in a report on Wednesday. Citigroup upped their price target on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Finally, Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a research note on Thursday, May 21st. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Roivant Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $35.14.
Check Out Our Latest Research Report on ROIV
About Roivant Sciences
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.
Further Reading
- Five stocks we like better than Roivant Sciences
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
